Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
This can lead to different kinds of anemia, fatigue, weakness, tingling in the fingers and toes, numbness, irregular heartbeat, mood swings, shortness of breath, very pale skin, memory loss, confusion, and more
A qualified buyer should request the COA for the exact lot and vial size that will ship
Thousands of members and counting Real members, real weight loss results Don't just take it from usour members see (and feel) the difference
Research into the individual peptides suggests distinct but potentially complementary mechanisms: Retatrutide through hormonal signaling for appetite and glucose, and MOTS-c through direct mitochondrial modulation and AMPK activation
Prescription Weight Loss Programs Tailored to You Losing weight solely through diet and exercise can be challenging
Future: Dedicated NASH Phase 3 Trial Expected Timeline IF Retatrutide Approved for Obesity/Diabetes (2028): 2027-2028: Dedicated NASH Phase 3 trial begins Population: Biopsy-confirmed NASH with fibrosis (F1-F3) Primary endpoint: NASH resolution without worsening fibrosis Baseline and Week 72-96 liver biopsies Duration: 18-24 months minimum 2029-2030: Trial results published 2030-2031: FDA approval decision for NASH indication Why This Matters Current Reality: Only one FDA-approved medication exists for NASH resmetirom (Rezdiffra), approved March 2024
